CLSA Asset Management Limited signed the share transfer agreement to acquire 5% stake in Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294) from Shenzhen Xinlitai Pharmaceutical Co., Ltd. for CNY 1.8 billion on September 1, 2020. Shenzhen Xinlitai Pharmaceutical plans to transfer 52.3 million shares at a transfer price was CNY 33.94 per share. CLSA Asset Management shall pay within 5 within working days from the delivery date through bank transfer. Shenzhen Xinlitai held 65.73% stake of Shenzhen Salubris before the transaction and will now hold 60.73% stake of Shenzhen Salubris.